Patents by Inventor Hakan Gunaydin

Hakan Gunaydin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250019380
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: July 13, 2022
    Publication date: January 16, 2025
    Inventors: Alessandro BOEZIO, Alexander M. TAYLOR, Cary Griffin FRIDRICH, Hakan GUNAYDIN, Lucian V. DIPIETRO, Levi Charles Thomas PIERCE, Mary M. MADER, Ravi KURUKULASURIYA, Thomas H. MCLEAN, Yue PAN, Michael Paul DENINNO, Alexandre LARIVEE, Andrew j. BURNIE, Caleb MEDENA, Gaetan MAERTENS, Kashif TANVEER, Mohan PAL, Tarek MOHAMED, Thomas LEPITRE, Bren-Jordan ATIENZA, Naresh VEMULA, Shorena GELOZIA
  • HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240308980
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 19, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kaleen Konrad Childers, J. Michael Ellis, Peter H. Fuller, Anmol Gulati, Hakan Gunaydin, Solomon D. Kattar, Ravi Kurukulasuriya, Joey L. Methot, Gregori J. Morriello, Santhosh Neelamkavil, Blair T. Lapointe, Vladimir Simov, Charles S. Yeung
  • SHP2 phosphatase inhibitors and methods of use thereof
    Patent number: 12084447
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: September 10, 2024
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240287058
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 29, 2024
    Inventors: Alessandro BOEZIO, Lucian V. DIPIETRO, Cary Griffin FRIDRICH, Hakan GUNAYDIN, Ravi KURUKULASURIYA, André LESCARBEAU, Mary M. MADER, Thomas H. MCLEAN, Levi CharlesThomas PIERCE, Kevin David RAYNOR, Kelley C. SHORTSLEEVES, Yong TANG, Alexander M. TAYLOR, W. Patrick WALTERS, Hanmo ZHANG, Fabrizio GIORDANETTO, Yakov PECHERSKY, Qi WANG, Bren-Jordan ATIENZA, Megan BERTRAND-LAPERLE, Andrew J. BURNIE, Fei CHEN, Sampada CHITALE, Shorena GELOZIA, Jean-Benoit GIGUERE, Elodie LANDAGARAY, Alexandre LARIVEE, Thomas LEPITRE, Gaetan MAERTENS, Johanne OUTIN, Mohan PAL, Claudio STURINO, Kashif TANVEER, Rakesh THORAT, Naresh VEMULA, Elaine B. KRUEGER, Yue PAN, Michael Paul DENINNO, Yves BOUSQUET, Antoine JOBIN-DES LAURIERS, Jessica LEE, Tarek MOHAMED
  • N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
    Patent number: 12030872
    Abstract: The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: July 9, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Vladimir Simov, William P. Kaplan, John J. Acton, III, Michael J. Ardolino, Joanna L Chen, Peter H. Fuller, Hakan Gunaydin, Derun Li, Ping Liu, Kaitlyn Marie Logan, Joey Methot, Gregori J. Morriello, Santhosh F. Neelamkavil, Luis Torres, Xin Yan, Hua Zhou
  • HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240174679
    Abstract: The present invention is directed to certain (hetero)aroyl 4-aminopyrazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: March 14, 2022
    Publication date: May 30, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kaleen Konrad Childers, J. Michael Ellis, Peter J. Fuller, Hakan Gunaydin, Jack D. Scott, Haiqun Tang, Charles S. Yeung
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230234958
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: December 15, 2022
    Publication date: July 27, 2023
    Inventors: Alexander M. Taylor, Andre Lescarbbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220340576
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: November 17, 2020
    Publication date: October 27, 2022
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220315586
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: March 21, 2019
    Publication date: October 6, 2022
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20210395236
    Abstract: The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Vladimir SIMOV, William P. KAPLAN, John J. ACTON, III, Michael J. ARDOLINO, Joanna L. CHEN, Peter H. FULLER, Hakan GUNAYDIN, Derun LI, Ping LIU, Kaitlyn Marie LOGAN, Joey METHOT, Gregori J. MORRIELLO, Santhosh F. NEELAMKAVIL, Luis TORRES, Xin YAN, Hua ZHOU
  • Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
    Patent number: 11174248
    Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: November 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Acton, David Annunziato Candito, J. Michael Ellis, Peter H. Fuller, Hakan Gunaydin, Blair T. Lapointe, Weiguo Liu, Joey L. Methot, Santhosh F. Neelamkavil, Barbara Pio, Vladimir Simov, Harold B. Wood
  • Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
    Patent number: 11161854
    Abstract: The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: November 2, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David Annunziato Candito, Thomas H. Graham, John Acton, Ryan Wing-Kun Chau, Joanna L. Chen, J. Michael Ellis, Peter H. Fuller, Anmol Gulati, Hakan Gunaydin, Solomon Kattar, Mitchell Henry Keylor, Blair T. Lapointe, Ping Liu, Weiguo Liu, Joey L. Methot, Santhosh F. Neelamkavil, Vladimir Simov, Ling Tong, Harold B. Wood
  • INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20210188818
    Abstract: The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: October 8, 2018
    Publication date: June 24, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John Acton, David Annunziato Candito, J. Michael Ellis, Peter H. Fuller, Hakan Gunaydin, Blair T. Lapointe, Weiguo Liu, Joey L. Methot, Santhosh F. Neelamkavil, Barbara Pio, Vladimir Simov, Harold B. Wood
  • INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20210188863
    Abstract: The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: October 8, 2018
    Publication date: June 24, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: David Annunziato Candito, Thomas H. Graham, John Acton, Ryan Wing-Kun Chau, Joanna L. Chen, J. Michael Ellis, Peter H. Fuller, Anmol Gulati, Hakan Gunaydin, Solomon Kattar, Mitchell Henry Keylor, Blair T. Lapointe, Ping Liu, Weiguo Liu, Joey L. Methot, Santhosh F. Neelamkavil, Vladimir Simov, Ling Tong, Harold B. Wood
  • KDM5 inhibitors
    Patent number: 10975084
    Abstract: The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: April 13, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Umar Faruk Mansoor, Christian Fischer, Phieng Siliphaivanh, Luis Torres, Hakan Gunaydin, David L. Sloman
  • ARGINASE INHIBITORS AND METHODS OF USE
    Publication number: 20210040127
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Christian A. Fischer, Symon Gathiaka, Hakan Gunaydin, Charles A. Lesburg, Derun Li, Min Lu, Anandan Palani, Rachel L. Palte, Qinglin Pu, David L. Sloman, Sung-Sau So, Chunrui Sun, Hongjun Zhang
  • Substituted indazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10689369
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: June 23, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
    Patent number: 10584121
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 10, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hongjun Zhang, Kenneth Jay Barr, Blair T. Lapointe, Hakan Gunaydin, Kun Liu, B. Wesley Trotter
  • KDM5 INHIBITORS
    Publication number: 20200048258
    Abstract: The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 13, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: UMAR FARUK MANSOOR, Christian Fischer, Phieng Siliphaivanh, Luis Torres, Hakan Gunaydin, David L. Sloman
  • KDM5 INHIBITORS
    Publication number: 20200048259
    Abstract: The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib): (I) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 13, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: UMAR FARUK MANSOOR, Christian Fischer, Phieng Siliphaivanh, Hakan Gunaydin